Showing results (51-60 of 125) with videos related to
Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancerAman Buzdar, Joyce A O'Shaughnessy, Daniel J Booser, et al.Cancer|September 16, 2011
Long-term outcomes in breast cancer patients undergoing immediate 2-stage expander/implant reconstruction and postmastectomy radiationAlice Ho, Peter Cordeiro, Joseph Disa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrheaChau Dang, Nancy Lin, Beverly Moy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancerMonica N Fornier, Andrew D Seidman, Diana Lake, et al.Breast Cancer Research and Treatment|August 22, 2017
Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302)Judith O Hopkins, Jake Allred, Arti Hurria, et al.Journal of Oncology Practice|July 31, 2014
Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance)Heidi D Klepin, Brandelyn N Pitcher, Karla V Ballman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104Ann H Partridge, Laura Archer, Alice B Kornblith, et al.The Lancet. Oncology|June 2, 2012
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpointsDebora Fumagalli, Philippe L Bedard, Zeina Nahleh, et al.Cancer Research|October 3, 2002
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancerLouise R Howe, Kotha Subbaramaiah, Jay Patel, et al.Breast Cancer Research : BCR|December 19, 2003
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatmentMark E Robson, Pierre O Chappuis, Jaya Satagopan, et al.Pageof 13